Diary - News
All news SynapCell and Motac Neuroscience Discover New Biomarker of Parkinson’s Disease Progression
Biomarker for Prodromal Disease Will Enable Industry to Assess Neuroprotective and Disease-Modifying Drugs
Chicago, IL -- Oct 21, 2019 -- SynapCell and Motac Neuroscience have discovered a new biomarker for progression of Parkinson’s Disease (PD). The BetaPark [evo] enables unprecedented opportunities for drug developers to test the neuroprotective or disease-modifying effects of their compounds. This discovery, combining Motac’s disease modeling and SynapCell’s EEG phenotyping capabilities, is being presented in a poster today in the Circuit Mechanisms of Motor Dysfunction in Parkinson's Disease Session (382.08/F23) of the Society for Neuroscience Annual Meeting in Chicago.
